Holen Sie sich die Stockscreener-App
5.77
3.38%
0.15
Handel nachbörslich:
5.66
-0.11
-1.91%
Schlusskurs vom Vortag:
$5.62
Offen:
$5.61
24-Stunden-Volumen:
197.87K
Relative Volume:
1.00
Marktkapitalisierung:
$50.03M
Einnahmen:
$137.27M
Nettoeinkommen (Verlust:
$-123.57M
KGV:
-0.5238
EPS:
-11.016
Netto-Cashflow:
$-102.89M
1W Leistung:
+0.69%
1M Leistung:
-9.92%
6M Leistung:
+38.00%
1J Leistung:
-54.43%
1-Tages-Spanne:
$5.51
$6.06
1-Wochen-Bereich:
$4.5101
$6.15
52-Wochen-Spanne:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.77 | 48.73M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Price momentum metrics for Karyopharm Therapeutics Inc. explainedMarket Risk Report & Free High Accuracy Swing Entry Alerts - newser.com
News impact scoring models applied to Karyopharm Therapeutics Inc.Portfolio Risk Summary & Stock Portfolio Risk Management - newser.com
Sector ETF performance correlation with Karyopharm Therapeutics Inc.Trade Entry Summary & Safe Investment Capital Preservation Plans - newser.com
Building trade automation scripts for Karyopharm Therapeutics Inc.2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
How Recent Developments Are Shaping the Karyopharm Therapeutics Investment Story - Yahoo
KPTI Receives Upgrade to 'Buy' from HC Wainwright & Co. | KPTI S - GuruFocus
Karyopharm Therapeutics stock rating upgraded to Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Upgrades Karyopharm Therapeutics (KPTI) - Nasdaq
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
HC Wainwright Upgrades Karyopharm Therapeutics to Buy From Neutral, $15 Price Target - MarketScreener
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickMarket Growth Summary & Precise Swing Trade Alerts - newser.com
What to expect from Karyopharm Therapeutics Inc. in the next 30 days2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
Using R and stats models for Karyopharm Therapeutics Inc. forecastingPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Heatmap analysis for Karyopharm Therapeutics Inc. and competitors2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Will Karyopharm Therapeutics Inc. continue its uptrend2025 Geopolitical Influence & Advanced Technical Analysis Signals - newser.com
Can a trend reversal in Karyopharm Therapeutics Inc. lead to recoveryPortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Karyopharm Secures $100M Financing for Clinical Trials - MSN
KPTI: Piper Sandler Reiterates Overweight Rating, Lowers Price T - GuruFocus
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
KPTI Strengthens Financial Position with $100M Capital Strategy - GuruFocus
Karyopharm Therapeutics stock price target lowered to $6 at Leerink Partners - Investing.com Canada
Karyopharm Raises $100M to Extend Cash Runway Through 2026Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm Announces Strategic Financing Transactions to Support Growth - citybiz
Karyopharm announces strategic financing - The Pharma Letter
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Three Months Ended September 30, 2025 - MarketScreener
Karyopharm secures $100 million in financing to extend cash runway By Investing.com - Investing.com Australia
Karyopharm stock falls after announcing $100 million financing deal By Investing.com - Investing.com Canada
$100M Financial Flexibility — Karyopharm Extends Runway into Q2 2026; SENTRY top-line due March 2026 - Stock Titan
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Karyopharm Therapeutics Inc. announced that it expects to receive $23.748952 million in funding - MarketScreener
Myelofibrosis Market Overview: Epidemiology, Therapies, - openPR.com
Is Karyopharm Therapeutics Inc. stock oversold or undervaluedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Will Karyopharm Therapeutics Inc. rebound enough to break evenGlobal Markets & AI Driven Price Predictions - newser.com
Measuring Karyopharm Therapeutics Inc.’s beta against major indicesQuarterly Trade Report & AI Driven Stock Movement Reports - newser.com
Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics - TipRanks
Using data filters to optimize entry into Karyopharm Therapeutics Inc. - newser.com
How Karyopharm Therapeutics Inc. (25K0) stock trades pre earningsJuly 2025 Institutional & Verified Trade Idea Suggestions - newser.com
Multi asset correlation models including Karyopharm Therapeutics Inc.July 2025 Closing Moves & Safe Entry Zone Tips - newser.com
Backtesting results for Karyopharm Therapeutics Inc. trading strategiesWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):